Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab +/- Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC
NCT07371897Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2026
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of toripalimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Event-Free Survival at 24 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07371897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371897.